特异性抗原激活的高效细胞毒性T淋巴细胞的实验研究

发布时间：2018-07-10 05:58

本文选题：特异性抗原 + 细胞毒性T淋巴细胞　；参考：《吉林大学》2007年博士论文

【摘要】： 本研究采用分子生物学、免疫学和微生物发酵技术，从人外周血中分离单个核细胞，经(1)rhHSP70-肿瘤肽复合物对淋巴细胞的有效激活；(2)槲寄生发酵提取物激活的共刺激分子的协同作用；(3)CD_3mAb及IL-2维持的大规模培养扩增，建立了特异性抗原激活的高效细胞毒性T淋巴细胞(SAA-CTL)的体外培养体系，经形态学观察、增殖动力学观察、免疫表型分析、细胞毒实验等一系列实验研究，结果表明，所建立的培养体系诱生了具有显著地特异性杀伤肿瘤细胞作用的淋巴细胞群，其免疫表型为CD_3~+CD_4~+、CD_3~+CD_8~+，，且从20ml外周血中即可扩增出10~9数量级的细胞，探讨了该法作为肿瘤辅助疗法的可行性，为其广泛应用于临床提供了依据。
[Abstract]:In this study, mononuclear cells were isolated from human peripheral blood by molecular biology, immunology and microbial fermentation, and activated by (1) rhHSP70- tumor peptide complex. (2) Synergistic effect of costimulatory molecules activated by fermentation extract of mistletoe, (3) Large-scale culture amplification of CD3mAb and IL-2 maintenance, in vitro culture system of highly effective cytotoxic T lymphocytes (SAA-CTL) activated by specific antigen was established and observed by morphology. A series of experimental studies, such as proliferation kinetics, immunophenotype analysis, cytotoxicity test and so on, showed that the established culture system induced the lymphocyte group which had a remarkable specific killing effect on tumor cells. The immunophenotype was CD3 ~ CD4 ~ tid _ 3 ~ CDC _ 8 ~, and 10 ~ 9 order of magnitude cells could be amplified from the peripheral blood of 20ml. The feasibility of this method as a tumor adjuvant therapy was discussed, which provided the basis for its wide application in clinical practice.
【学位授予单位】：吉林大学
【学位级别】：博士
【学位授予年份】：2007
【分类号】：R392

【参考文献】